• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

SymphonyRM Raises $25M for Engagement Tool

Share:

May 26, 2021

SymphonyRM, a Palo Alto, CA-based provider of AI-powered patient engagement solutions for health systems, raised $25m in Series B funding.

The round was led by new investment partner TT Capital Partners (TTCP) with continued investment from Adams Street Partners.

The company intends to use the funds to accelerate sales and marketing efforts and to increase its reach and presence in the payer segment.

Led by Michael Linnert, CEO, SymphonyRM provides health systems with a platform to acquire, engage, and retain patients. By generating data-driven, prioritized next best actions for every consumer, prospect, and provider in a health system, the solution enables organizations to anticipate member needs and use proactive outreach to build deeper customer relationships and drive outcomes while increasing revenue.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Source: Finsmes

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • ELNA Medical Acquires the Network of PrivaMED Medical ClinicsELNA Medical Acquires the Network of PrivaMED Medical Clinics
  • Jumping to Lightspeed – Consolidating Patient Monitoring DevicesJumping to Lightspeed – Consolidating Patient Monitoring Devices
  • BioVie Announces Closing of Acquisition of Biopharma Assets from Privately Held NeurMedixCompany Expects to Commence Enrollment in Pivotal Phase 3 Alzheimer’s Trial in Mid-2021BioVie Announces Closing of Acquisition of Biopharma Assets from Privately Held NeurMedixCompany Expects to Commence Enrollment in Pivotal Phase 3 Alzheimer’s Trial in Mid-2021
  • Why the Digital Front Door is Critical to the Healthcare Revenue CycleWhy the Digital Front Door is Critical to the Healthcare Revenue Cycle
  • Philips, Disney Partner to Improve Pediatric Experience During MRI ExamsPhilips, Disney Partner to Improve Pediatric Experience During MRI Exams
  • Bioventus Amends Cartiheal Acquisition StructureBioventus Amends Cartiheal Acquisition Structure
  • Livongo Taps MDLive, Doctor on Demand for Virtual Care IntegrationLivongo Taps MDLive, Doctor on Demand for Virtual Care Integration
  • Edwards Lifesciences to buy heart device maker for $400 millionEdwards Lifesciences to buy heart device maker for $400 million

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications